TrialJournal of Korean medical science2017

Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness.

Yong Ho Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.